Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

@article{Bhavnani2012PharmacologicalAP,
  title={Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.},
  author={Sujata M. Bhavnani and Christopher M. Rubino and Jeffrey P. Hammel and Alan Forrest and Nathalie Dartois and C Angel Cooper and Joan M Korth-Bradley and Paul Ambrose},
  journal={Antimicrobial agents and chemotherapy},
  year={2012},
  volume={56 2},
  pages={
          1065-72
        }
}
Pharmacokinetic and clinical data from tigecycline-treated patients with hospital-acquired pneumonia (HAP) who were enrolled in a phase 3 clinical trial were integrated in order to evaluate pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy. Univariable and multivariable analyses were conducted to identify factors associated with clinical and microbiological responses, based on data from 61 evaluable HAP patients who received tigecycline intravenously as a 100-mg loading dose… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Busting the Myth of "Static vs Cidal": A Systemic Literature Review.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections. Drugs Aging 28:903–912

Q Zhou
  • 2011
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

What is ventilator-associated pneumonia and why is it important?

  • Respiratory care
  • 2005
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL